OJJAARA momelotinib

Drug Class

JAK1/JAK2 and ACVR1 inhibitor

Mechanism

Inhibits JAK1, JAK2, and ACVR1 (ALK2), reducing cytokine-mediated signaling and lowering hepcidin levels to address anemia and splenomegaly.

Approved Indication

Treatment of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis, in adults with anemia.

What This Means For Patients

Ojjaara (momelotinib) is a targeted oral kinase inhibitor for patients with intermediate or high-risk myelofibrosis who also suffer from anemia. It works by shrinking the enlarged spleen and stimulating red blood cell production. It is available under the special-import policy in the Hainan Boao Lecheng pilot zone.

Regulatory Approvals

• FDA — approved (2023) — label
• EMA — approved (2024) — source

Pivotal Clinical Evidence

• MOMENTUM — Verstovsek et al., Lancet 2023 (NCT04173494) — DOI

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218025s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/omjjara